RARRES2 and neoplasm: Taken together, these data suggest that loss of chemerin/RARRES2 expression occurs in breast cancer during tumorigenesis, potentially as an immune evasion mechanism, and that restoring or enhancing chemerin levels within the TME may prove efficacious in increasing TIL, thereby slowing or reversing tumor progression in the clinic.